We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Showcases Extensive Range of Revolutionary Diagnostic Analyzers at MEDICA 2021

By LabMedica International staff writers
Posted on 16 Nov 2021
Print article
Image: RX monaco Compact Fully Automated Solution (Photo courtesy of Randox Laboratories)
Image: RX monaco Compact Fully Automated Solution (Photo courtesy of Randox Laboratories)

Randox Laboratories (Crumlin, UK) shared a wealth of new products and innovative technologies with the industry at the 2021 edition of MEDICA. More than 5,000 exhibitors from 70 countries presented their newest products and ideas at MEDICA which drew 120,000 trade visitors from over 170 countries.

At MEDICA 2021, Randox presented the Discovery benchtop lab, an exciting and disruptive molecular & immunoassay diagnostic analyzer capable of consolidating the normal workload of multiple laboratories, into one compact benchtop platform. Randox’s patented Biochip technology allows simultaneous detection of hundreds of targets from a single patient sample. The benefits of multiplexing in this way are endless; allows complete patient profiling, reduces the amount of time spent on individual tests, identifies co-infections, differentiates between pathogens that exhibit similar symptoms and eliminates the need to run multiple time consuming and sample intensive assays. The biochip detection system is based on a chemiluminescent signal, this is the emission of light, without heat, as a result of a chemical reaction.

Randox also showcased the RX misano semi-automated clinical chemistry analyzer that shines a new light on semi-automated clinical chemistry testing with increased auto-functionality and groundbreaking technology. Among other products exhibited at the event by Randox were the RX daytona+ fully automated analyzer that performs a wide range of niche and specialized routine chemistries, specific proteins, lipids, therapeutic drugs, antioxidants, diabetes and veterinary testing; and the RX monaco compact fully automated solution that comprises an extensive test menu covering routine chemistries, specific proteins, lipids, antioxidants, diabetes and veterinary testing with emergency and STAT sampling.

Among its extensive range of diagnostic tests, Randox highlighted its newly-launched Vivalytic Extensive SARS-CoV-2 pooling test which is a rapid real-time PCR test cartridge that provides clear and concise results in a timely manner, direct at the point of care on the Vivalytic instrument. The SARS-CoV-2 polling test with lollipop swab allows for the screening of up to 15 patient samples. One of the first rapid pooling PCR tests on the market, the Vivalytic produces results in less than 45 minutes delivering high accuracy for extensive and faster testing ideal for rapid and confirmatory SARS-CoV-2 screening in any environment.

Related Links:
Randox Laboratories

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more